Validation of DNA promoter hypermethylation biomarkers in breast cancer -a short report

详细信息    查看全文

• 作者：Jolien S. de Groot ; Xiaojuan Pan ; Jan Meeldijk ; Elsken van der Wall…
• 关键词：Breast cancer ; Early detection ; DNA promoter hypermethylation ; Biomarkers ; Validation
• 刊名：Cellular Oncology
• 出版年：2014
• 出版时间：August 2014
• 年：2014
• 卷：37
• 期：4
• 页码：297-303
• 全文大小：640 KB
• 参考文献：1. WHO, Breast cancer: prevention and control. http://www.who.int/cancer/detection/breastcancer/en/. Accessed 30 June 2014
  2. A. Algamas-Dimantov, E. Yehuda-Shnaidman, I. Peri, B. Schwartz, Epigenetic control of HNF-4alpha in colon carcinoma cells affects MUC4 expression and malignancy. Cell. Oncol. 36, 155-67 (2013) CrossRef
  3. Y. You, W. Yang, Z. Wang, H. Zhu, H. Li, C. Lin, Y. Ran, Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas. Cell. Oncol. 36, 323-31 (2013) CrossRef
  4. L.H. Jensen, A.A. Rasmussen, L. Byriel, H. Kuramochi, D.G. Cruger, J. Lindebjerg, P.V. Danenberg, A. Jakobsen, K. Danenberg, Regulation of MLH1 mRNA and protein expression by promoter methylation in primary colorectal cancer: A descriptive and prognostic cancer marker study. Cell. Oncol. 36, 411-19 (2013) CrossRef
  5. A. Geurts van Kessel, The cancer genome: From structure to function. Cell. Oncol. 37, 155-65 (2014) CrossRef
  6. K.P. Suijkerbuijk, M.J. Fackler, S. Sukumar, C.H. van Gils, T. van Laar, E. van der Wall, M. Vooijs, P.J. van Diest, Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer. Ann. Oncol. 19, 1870-874 (2008) CrossRef
  7. J.G. Herman, J.R. Graff, S. Myohanen, B.D. Nelkin, S.B. Baylin, Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. U. S. A. 93, 9821-826 (1996) CrossRef
  8. D.S. Shames, J.D. Minna, A.F. Gazdar, Methods for detecting DNA methylation in tumors: From bench to bedside. Cancer Lett. 251, 187-98 (2007) CrossRef
  9. P.J. van Diest, No consent should be needed for using leftover body material for scientific purposes. BMJ 325, 648-51 (2002) CrossRef
  10. T. Swift-Scanlan, R. Vang, A. Blackford, M.J. Fackler, S. Sukumar, Methylated genes in breast cancer: Associations with clinical and histopathological features in a familial breast cancer cohort. Cancer Biol. Ther. 11, 853-65 (2011) CrossRef
  11. M.J. Fackler, C.B. Umbricht, D. Williams, P. Argani, L.A. Cruz, V.F. Merino, W.W. Teo, Z. Zhang, P. Huang, K. Visvananthan, J. Marks, S. Ethier, J.W. Gray, A.C. Wolff, L.M. Cope, S. Sukumar, Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res. 71, 6195-207 (2011) CrossRef
  12. M.J. Fackler, Z.L. Bujanda, C. Umbricht, W.W. Teo, S. Cho, Z. Zhang, K. Visvanathan, S. Jeter, P. Argani, C. Wang, J.P. Lyman, M. de Brot, J.N. Ingle, J. Boughey, K. McGuire, T.A. King, L.A. Carey, L. Cope, A.C. Wolff, S. Sukumar, Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res. 74, 2160-170 (2014) CrossRef
  13. NCBI Gene, AKR1B1 aldo-keto reductase family 1, member B1 (aldose reductase) [ / Homo sapiens (human)]. http://www.ncbi.nlm.nih.gov/gene/231. Accessed 30 June 2014
  14. R. Tammali, S.K. Srivastava, K.V. Ramana, Targeting aldose reductase for the treatment of cancer. Curr. Cancer Drug Targets 11, 560-71 (2011) CrossRef
  15. N. Hevir, J. Sinkovec, T. Lanisnik Rizner, Decreased levels of AKR1B1 and AKR1B10 in cancerous endometrium compared to adjacent non-cancerous tissue. Chem. Biol. Interact. 202, 226-33 (2013) CrossRef
  16. B. Laffin, J.M. Petrash, Expression of the Aldo-Ketoreductases AKR1B1 and AKR1B10 in Human Cancers. Front. Pharmacol. 3, 104 (2012)
  17. R. Tao, J. Li, J. Xin, J. Wu, J. Guo, L. Zhang, L. Jiang, W. Zhang, Z. Yang, L. Li, Methylation profile of single hepatocytes derived from hepatitis B virus-related hepatocellular carcinoma. PLoS One 6, e19862 (2011) CrossRef
  18. F. Fang, S. Turcan, A. Rimner, A. Kaufman, D. Giri, L.G. Morris, R. Shen, V. Seshan, Q. Mo, A. Heguy, S.B. Baylin, N. Ahuja, A. Viale, J. Massaque, L. Norton, L.T. Vahdat, M.E. Moynahan, T.A. Chan, Breast cancer methylomes establish an epigenomic foundation for metastasis. Sci. Transl. Med. 3, 75ra25 (2011)
  19. R.T. Chatterton, M. Sahadevan, O. Lee, H. Hong, W. Jun, I. Helenowski, S. Sukumar, V. Stearns, M.J. Fackler, S.A. Khan, Single-strand breaks in normal breast DNA are associated with measures of breast cancer risk, deficiencies in repair mechanisms, and diminished protection against oxidative processes. Cancer Prev. Res. 5, A15 (2012) CrossRef
  20. S.K. Botla, A.M. Gholami, M. Malekpour, E.A. Moskalev, M. Fallah, P. Jandaghi, A. Aghajani, I.S. Bondar, R. Omranipour, F. Malekpour, A. Mohajeri, A.J. Bababi, O. Sahin, V.V. Bubnov, H. Najmabadi, J.D. Hoheisel, Y. Riazalhosseini, Diagnostic values of GHSR DNA methylation pattern in breast cancer. Breast Cancer Res. Treat. 135, 705-13 (2012) CrossRef
  21. J. Jeschke, L. van Neste, S.C. Glockner, M. Dhir, M.F. Calmon, V. Deregowski, W. van Criekinge, I. Vlassenbroeck, A. Koch, T.A. Chan, L. Cope, C.M. Hooker, K.E. Schuebel, E. Gabrielson, A. Winterpacht, S.B. Baylin, J.G. Herman, N. Ahuja, Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. Epigenetics 7, 701-09 (2012) CrossRef
  22. S.Y. Park, H.J. Kwon, H.E. Lee, H.S. Ryu, S.W. Kim, J.H. Kim, I.A. Kim, N. Jung, N.Y. Cho, G.H. Kang, Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch. 458, 73-4 (2011) CrossRef
  23. R. Krassenstein, E. Sauter, E. Dulaimi, C. Battagli, H. Ehya, A. Klein-Szanto, P. Cairns, Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin. Cancer Res. 10, 28-2 (2004) CrossRef
  24. M. Faryna, C. Konermann, S. Aulmann, J.L. Bermejo, M. Brugger, S. Diederichs, J. Rom, D. Weichenhan, R. Claus, M. Rehli, P. Schirmacher, H.P. Sinn, C. Plass, C. Gerhauser, Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. FASEB J. 26, 4937-950 (2012) CrossRef
  25. M.S. Kim, J. Lee, T. Oh, Y. Moon, E. Chang, K.S. Seo, B.D. Hoehn, S. An, J.H. Lee, Genome-wide identification of OTP gene as a novel methylation marker of breast cancer. Oncol. Rep. 27, 1681-688 (2012)
  26. H.N. Horne, P.S. Lee, S.K. Murphy, M.A. Alonso, J.A. Olson, J.R. Marks, Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. Mol. Cancer Res. 7, 199-09 (2009) CrossRef
  27. C. Fumagalli, G. Pruneri, P. Possanzini, M. Manzotti, M. Barile, I. Feroce, M. Colleoni, B. Bonnani, P. Maisonneuve, P. Radice, G. Viale, M. Barberis, Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients. Breast Cancer Res. Treat. 134, 131-37 (2012) CrossRef
  28. J. Klajic, T. Fleischer, E. Dejeux, H. Edvardsen, F. Warnberg, I. Bukholm, P.E. Lonning, H. Solvang, A.L. Borresen-Dale, J. Tost, V.N. Kristensen, Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors. BMC Cancer 13, 1-2 (2013) CrossRef
  29. Y. Alkam, H. Mitomi, K. Nakai, T. Himuro, T. Saito, M. Takahashi, A. Arakawa, T. Yao, M. Saito, Protein expression and methylation of DNA repair genes hMLH1, hMSH2, MGMT and BRCA1 and their correlation with clinicopathological parameters and prognosis in basal-like breast cancer. Histopathology 63, 713-25 (2013)
  30. A. Tserga, N.V. Michalopoulos, G. Levidou, P. Korkolopoulou, G. Zografos, E. Patsouris, A.A. Saetta, Association of aberrant DNA methylation with clinicopathological features in breast cancer. Oncol. Rep. 27, 1630-638 (2012)
  31. G. Sharma, S. Mirza, R. Parshad, A. Srivastava, S.D. Gupta, P. Pandya, R. Ralhan, Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sci. 87, 83-1 (2010) CrossRef
  32. A.A. Muggerud, J.A. Ronneberg, F. Warnberg, J. Botling, F. Busato, J. Jovanovic, H. Solvang, I. Bukholm, A.L. Borresen-Dale, V.N. Kristensen, T. Sorlie, J. Tost, Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res. 12, R3 (2010) CrossRef
  
• 作者单位：Jolien S. de Groot (1)
  Xiaojuan Pan (1)
  Jan Meeldijk (1)
  Elsken van der Wall (2)
  Paul J. van Diest (1)
  Cathy B. Moelans (1)
  
  1. Department of Pathology, University Medical Center Utrecht, H04.312, PO Box 85500, 3508, GA, Utrecht, the Netherlands
  2. Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands
  
• ISSN：2211-3436

文摘

Purpose DNA promoter hypermethylation of tumor suppressor genes is known to occur early in cancer development, including breast cancer. To improve early breast cancer detection, we aimed to investigate whether the identification of DNA promoter hypermethylation might be of added value. Methods The methylation status of a panel of 19 candidate genes (AKR1B1, ALX1, ARHGEF7, FZD10, GHSR, GPX7, GREM1, GSTP1, HOXD1, KL, LHX2, MAL, MGMT, NDRG2, RASGRF2, SFRP1, SFRP2, TM6SF1 and TMEFF2) was determined in formalin-fixed paraffin-embedded normal breast and breast cancer tissue samples using gel-based methylation-specific PCR (MSP). Results The promoters of the AKR1B1, ALX1, GHSR, GREM1, RASGRF2, SFRP2, TM6SF1 and TMEFF2 genes were found to be significantly differentially methylated in normal versus malignant breast tissues. Based on sensitivity, specificity and logistic regression analyses the best performing genes for detecting breast cancer were identified. Through multivariate analyses, we found that AKR1B1 and TM6SF1 could detect breast cancer with an area under the curve (AUC) of 0.986 in a receiver operating characteristic (ROC) assessment. Conclusions Based on our data, we conclude that AKR1B1 and TM6SF1 may serve as candidate methylation biomarkers for early breast cancer detection. Further studies are underway to evaluate the methylation status of these genes in body fluids, including nipple aspirates and blood.